Pfizer drug effective in patients with rare lung cancer: study

Pfizer drug effective in patients with rare lung cancer: study

By Bill Berkrot (Reuters) - Pfizer Inc's Xalkori, which treats lung cancer patients with a specific gene mutation, proved effective in shrinking tumors in those with an even rarer form of the disease, according to data presented at a medical meeting on Saturday. In the study of 50 non-small cell lung cancer patients with a rearrangement of the ROS1 gene, Xalkori treatment led to significant tumor shrinkage in 36 of them, or 72 percent, and halted tumor growth in an additional 9 patients, researchers reported. ...

Early data promising for AstraZeneca cancer drug combination

By Ben Hirschler MADRID (Reuters) - Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system show the cocktail is promising, though limited patient numbers mean the data is far from conclusive. The British drugmaker, which fended off a $118 billion (72.64 billion pound) takeover bid from Pfizer in May in part by talking up its cancer drug prospects, has high hopes for the combination of two experimental drugs known as MEDI4736 and tremelimumab. ...

You are reading an article about Pfizer drug effective in patients with rare lung cancer: study and you can find this article in url https://we-care-you.blogspot.com/2014/09/pfizer-drug-effective-in-patients-with.html,You can copy paste and use the article Pfizer drug effective in patients with rare lung cancer: study , may this is very interesting for you and others ,but don't forget to take this link Pfizer drug effective in patients with rare lung cancer: study for article source, Thanks.